• onset
  • I. To investigate how donor killer-cell immunoglobulin-like receptors (KIR) genes of interest (activating KIR2DS2 and 2DS4, inhibitory KIR2DL1, 2DL2/2DL3, 3DL1, 3DL2), together with their recipient ligands where known, influence CMV reactivation-free survival after allogeneic HCT, independently of clinical risk factors such as onset of acute graft-versus-host disease. (clinicaltrials.gov)
  • somatic
  • Determine the effects of SAHA on induction of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-death receptors DR4 and DR5 and other pro-apoptotic mediators in patient-derived cancer cells (leukemia blast cells) and somatic cells (buccal mucosa cells, using pre-SAHA and on SAHA treatment samples). (clinicaltrials.gov)
  • blood
  • Researchers at the University of Cincinnati (UC) College of Medicine and Cincinnati Children's Hospital Medical Center have discovered a target in several types of leukemia that could be treated with an existing Food and Drug Administration (FDA)-approved drug for other types of blood cancers. (medicalxpress.com)
  • cell
  • The National Cancer Institute has tested over 90,000 extracts of terrestrial plants and marine plants and invertebrates in its human cancer one-dose/60-cell-line prescreen, and the results for plants and marine organisms meeting criteria established for activity against selected leukemia cell lines are presented. (readbyqxmd.com)
  • Dysregulated signaling, proliferation and apoptosis impact on the pathogenesis of TCRgammadelta+ T cell large granular lymphocyte leukemia. (amedeo.com)